AdvisorShares Psychedelics ETF
$24.11−0.94 (−3.73%)
- Expense ratio
- 1.84%
- Fund size
- $57M
- 1Y return
- +56.2%
- Yield · Last 12 months
- 6.72%
- Holdings
- 25
- Volume · 30D
- 0M sh
- NAV per share
- $24.68
- 52W range
The ETF.net PSIL Grade
Score 18 of 100 sits in the F band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.FScore 6Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.FScore 21Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.FScore 22Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.DScore 39Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.DScore 28Category rank
Our read on PSIL
FThe ticker is the thesis. PSIL is a compact, global, actively run basket of health care companies working on psychedelic medicine, with a stated goal of long-term capital appreciation in a corner of the market almost no other ETF touches.
The Fund seeks long-term capital appreciation.
Why people hold it
- One ticker, the whole theme: a global basket of roughly two dozen health care names tied to psychedelic medicine, instead of hand-picking single clinical-stage stocks.advisorshares.com
- Concentrated on purpose. At around 25 positions, the theme stays front and center rather than getting diluted inside a broad mega-cap pharma index.
- Trading since 2021, so there is multi-year live operating history behind the strategy, not a simulated one.
Worth knowing
- Expensive by pharma-ETF standards: 1.84% a year, against 0.36% at PPH and 0.35% at XPH. A niche, actively managed mandate carries a niche price tag.
- Small asset base and light trading volume. Spreads can be wide, so limit orders are the standard way to deal with a fund this thinly traded.
- Within its pharma and therapeutics peer group it sits in the bottom quartile, held back mainly by cost and tradability rather than the theme itself.
PSIL Holdings
- Stocks
- 25
- 67%
- CMPS
Sectors
Geography
PSIL Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PSIL |
|---|---|
| Year to date | +45.9% |
| 1 month | −3.1% |
| 3 months | +17.3% |
| 1 year | +56.2% |
| 3 years | +19.6% |
| 5 years | −22.6% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PSIL |
|---|---|---|
| 2026 YTD | +45.9% | |
| 2025 | +74.1% | |
| 2024 | −19.5% | |
| 2023 | −25.3% | |
| 2022 | −67.9% | |
| 2021 | −42.0% |
PSIL in the news
ETF.net Research hasn’t filed on PSIL yet — coverage lands here as it’s written.
PSIL Dividends
- 6.72%
- $1.68
- $1.68 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Dec 22, 2025 | Dec 29, 2025 | $1.68 |
| Sep 22, 2025 | Sep 29, 2025 | $0.02 |
| Jun 23, 2025 | Jun 27, 2025 | $0.01 |
| Mar 21, 2025 | Mar 28, 2025 | $0.16 |
| Dec 23, 2024 | Dec 30, 2024 | $0.05 |
| Sep 23, 2024 | Sep 30, 2024 | $0.11 |
| Sep 25, 2023 | Sep 29, 2023 | Data unavailable |
| Sep 26, 2022 | Sep 30, 2022 | Data unavailable |
PSIL Risk
- 46.9%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.43
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −92.9%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.56
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PSIL Cost
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
Every other Pharma & Therapeutics fund charges less.